JY
ASBPW

Jeff Yass’s Aspire Biopharma Warrant ASBPW Stock Holding History

Jeff Yass’s Portfolio ASBPW Stock Details ASBPW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-16,781
Closed -$279 – 14854
2026
Q1 		$279 Buy
+16,781
New +$342 ﹤0.01% 13053
2025
Q4 		– Sell
-57,932
Closed -$1.73K – 14004
2025
Q3 		$1.73K Buy
+57,932
New +$2.93K ﹤0.01% 12178
2024
Q1 		– Sell
-23,803
Closed -$1.43K – 13585
2023
Q4 		$1.43K Sell
23,803
-2,547
-10% -$105 ﹤0.01% 12187
2023
Q3 		$1.32K Sell
26,350
-7,583
-22% -$612 ﹤0.01% 11868
2023
Q2 		$1.7K Buy
+33,933
New +$1.25K ﹤0.01% 11878

Other funds holding ASBPW

SCM
Saba Capital Management New York $3.9B AUM 12.9% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
LA
Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.48% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
SC
Sculptor Capital New York $12.3B AUM 40.26% 1-Year Est. Return
CS
Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return

Jeff Yass's ASBPW Position: Q2 2026 in Review

Jeff Yass sold out of Aspire Biopharma Warrant (ASBPW) in Q2 2026, closing a stake of 16,781 shares — an estimated $279 sold.

Jeff Yass first reported a position in ASBPW in Q2 2023 and held it in 5 quarters. The position peaked at $1.73K in Q3 2025. 27 funds tracked by Wall St. Rank hold ASBPW as of Q2 2026.

  • Jeff Yass reported no remaining Aspire Biopharma Warrant position as of Q2 2026 after selling out during the quarter.
  • Jeff Yass sold 16,781 Aspire Biopharma Warrant shares in Q2 2026, an estimated $279.
  • Jeff Yass first reported a position in Aspire Biopharma Warrant in Q2 2023 and held it in 5 quarters.
  • Jeff Yass's Aspire Biopharma Warrant position peaked at $1.73K in Q3 2025.
  • 27 funds tracked by Wall St. Rank held Aspire Biopharma Warrant as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.